Navigation Links
Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
Date:6/4/2010

ve cancer therapies like these to cancer patients around the world," said Mel Sorensen, M.D., President and Chief Executive Officer of Ascenta Therapeutics. "Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction offers the potential to control and prevent cancer progression. We are delighted to have sanofi-aventis join us and the University of Michigan in this endeavor to turn exciting science into novel cancer medicines."

About HDM2/p53 Inhibition

Inhibiting the interaction between p53 and HDM2 (human double minute 2, and its murine counterpart, MDM2) is a very promising approach to restoring the natural tumor suppression function of the p53 protein.  The p53 tumor suppressor is a principal mediator of growth arrest, senescence, and apoptosis in response to cellular damage. It is called the "guardian of the genome" because of its role in controlling the cell cycle and monitoring the integrity of the genome. HDM2 is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function. Loss of p53 function is involved in 50 percent of cancers, either through mutation, overexpression or amplification of HDM2 in wild-type p53 tumors.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).  For more information, please visit: www.san
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
2. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
3. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
6. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
7. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
8. Trius Therapeutics Awarded U.S. Department of Defense Contract to Develop Novel Antibiotics
9. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
10. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
11. Nile Therapeutics Announces Exercise of Over-Allotment Option for Recent Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
(Date:8/28/2014)... 2014  Armetheon, Inc. ( www.armetheon.com ), a ... late-stage cardiovascular drug candidates, today announced that it ... of financing. The Series A round was co-led ... participation from investors that included Atheneos Capital and ... Larry Hsu , the founder of Impax Laboratories. ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... March 14, 2010 Cardiovascular risk can,be reduced ... with,atherogenic dyslipidemia, the common combination of elevated triglycerides,(TG, 204 mg/dL ... cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower). This ... patients need,to be treated for 5 years to prevent one ...
... ... CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough of Manhattan Community College (BMCC) ... 2009 CUNY Nobel Science Challenge—as well as $5,000 as an overall Grand Prizewinner., , , ...
... Medicare will cover OVA1™, a test to help assess the likelihood that an ovarian mass is benign or malignant. Highmark Medicare Services is ... ... , , ... ...
Cached Biology Technology:ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 2ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 3ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 4ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 5ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 6ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 7ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 8ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation 9BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test 2Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test 3Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test 4
(Date:8/29/2014)... Dartmouth researchers explored the type and number of connections ... assortativity plays on robustness in a study published in ... study found that the assortativity signature contributes to a ... seems that varying the out-out assortativity of TFN models ... of the other three types of assortativity," said Dov ...
(Date:8/29/2014)... MO. - In a cell,s nucleus, chromosomal DNA ... histones, an amalgam biologists call chromatin. Until about ... nuclear "sidekick," the mere packing material around which ... biologists have developed a greater appreciation for how ... investigators from multiple research institutions studying the sequence ...
(Date:8/28/2014)... to announce the selection of Dr. Fred Baxendale as ... those who have served ESA for at least 20 ... Society that has reached an extraordinary level. Candidates for ... and then voted on by the ESA membership. Dr. ... Entomology 2014, ESA,s Annual Meeting in Portland, Oregon this ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... and the U.S.A., the scientists have shown how cutting-edge ... of active proteins in cell organelles at a particular ... use proteins. The work is published in the journal ... cities. They contain all the necessary parts that allow ...
... the use of liquid crystalline polymers (LCP) as a ... sought-after lab-on-a-chip technology. , University of Alberta researchers, collaborating ... Phillips Research Laboratories in the Netherlands, have shown that ... glass backing, can be fabricated and patterned on a ...
... of dengue fever wax and wane over a period ... why. With the incidence and range of the potentially ... these epidemics has never been more important. , A ... suggests that a brief period of cross-immunity conferred by ...
Cached Biology News:A catalogue of proteins 2Polymers show promise for lab-on-a-chip technology 2UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
Small bottle for hybridization 150 x 35mm...
... have the durability to run ... and the uniformity and contamination ... applications. Heavily built with ... stackers are designed for ease ...
CQCS kit for first KR 4i , (first unit)....
Biology Products: